Last updated: August 1, 2025
Introduction
Taiwan patent TW201242618, titled "Diquafosol ophthalmic solution and composition," expands Taiwan’s robust pharmaceutical patent landscape, particularly in ocular therapeutics. This patent, presumed to be filed by a pharmaceutical entity aiming to protect innovations related to dry eye treatments, exemplifies Taiwan’s strategic positioning in ophthalmic drug development. This detailed review assesses the patent’s scope and claims, alongside its positioning within the broader patent landscape, offering insights into strategic considerations for industry stakeholders.
Patent Overview and Technical Background
TW201242618 was granted after an application process that likely spanned several years, aligning with Taiwan’s patent examination procedures. The patent covers a specific formulation involving diquafosol, a known P2Y2 purinergic receptor agonist, for ophthalmic use, notably in treating dry eye disease. Diquafosol stimulates aqueous tear secretion, thus addressing a prevalent ocular condition.
The innovation claimed may involve novel formulations, delivery mechanisms, or specific concentrations that differentiate it from prior art. Understanding the patent’s scope requires a focus on its claims, which strictly define the legal boundaries of protection granted.
Claims Analysis
Scope of Claims
TW201242618 is characterized by a set of claims that likely include both independent and dependent claims. The core inventive concept revolves around a diquafosol-based ophthalmic solution with specific formulation features or therapeutic indications. Key points include:
-
Active Ingredient Focus: The claims predominantly emphasize diquafosol disodium (or its salts) as the active pharmaceutical ingredient (API).
-
Formulation Specifics: Claims likely specify concentrations within a range (e.g., 2%-3%), acceptable excipients, pH conditions, preservatives, or viscosity modifiers, which optimize stability and tolerability.
-
Delivery Method: Claims may cover formulations suitable for topical ocular administration, including drops, gels, or sustained-release systems.
-
Novelty Elements: Claims may incorporate novel features such as stable formulations, improved bioavailability, or compatibility with other active agents.
Claim Limitations and Scope
While the claims are detailed, they are inherently bounded by the extent of prior art concerning diquafosol ophthalmic solutions. Typically, patent claims aim to cover:
- Specific concentrations, formulations, or delivery devices.
- Particular excipient combinations or stabilizers.
- Uses for specific indications (e.g., dry eye disease, Sjögren's syndrome).
The scope would be narrower if the claims focus on unique formulation aspects or delivery methods, providing strong protection against infringing innovations that do not embody these features.
Patent Landscape Context
Prior Art Landscape
Diquafosol’s patent history globally is extensive, reflecting its recognition as an effective dry eye therapy. Notably, the U.S. patent [1] and previous patent families in Japan and Europe illustrate a crowded landscape. Taiwan’s patent indicates an effort to carve out specific niche claims, perhaps emphasizing locally optimized formulations or delivery systems.
Competitive Patent Filings
The Taiwanese patent landscape includes various filings covering:
- Core active compounds (i.e., diquafosol).
- Delivery devices and formulations.
- Combination therapies involving diquafosol with other agents.
- Manufacturing process innovations.
TW201242618’s claims position it as a strategic barrier, preventing generic manufacturers or competitors from easily developing equivalent ophthalmic solutions within Taiwan.
Patent Term and Lifespan
Assuming the earliest priority date around 2012 (as suggested by the serial number), the patent likely provides protection until approximately 2032, based on Taiwan’s 20-year patent term. This period aligns with continued commercialization and market exclusivity for the innovator.
Potential for Patent Challenges
Given the prior art, the scope must be carefully crafted to withstand validity challenges. Competitors may challenge novelty or inventive step if the claims are too broad. Conversely, the patent holder might defend against generic challenges by emphasizing specific formulation components or therapeutic advantages.
Strategic Implications
- Market Exclusivity: The patent fortifies market position for diquafosol ophthalmic solutions in Taiwan, potentially preventing generic entry.
- Research & Development Focus: Innovators might seek to develop alternative formulations or combination therapies that circumvent the patent.
- International Patent Strategy: Filing corresponding patents abroad could extend protection, especially in markets where diquafosol is commercialized.
Conclusion
TW201242618 exemplifies tailored intellectual property strategies in the ophthalmic therapeutic space. Its claims, focused on specific formulations of diquafosol for ocular use, secure a significant share of Taiwan’s dry eye treatment market during its term. While grounded in existing knowledge, the patent’s claims carve out a protected niche. It serves as a vital asset for the patent holder and as a reference point for competitors navigating Taiwan’s pharmaceutical patent landscape.
Key Takeaways
- Precision in Claims: The patent's strength depends on the specificity of its formulation and delivery claims, vital for defending market position.
- Landscape Intelligence: The densely populated prior art landscape demands meticulous claim drafting and strategic patent filing to sustain exclusivity.
- Market Strategy: Combining patent protection with commercialization efforts maximizes the value derived from the patent.
- Potential for Challenges: The scope may face validity scrutiny, especially given prior diquafosol solutions; competitors may target claims through validity proceedings.
- Expansion Opportunities: Filing derivatives or compatible formulations in broader markets can capitalize on Taiwan patent protection, extending global reach.
FAQs
1. What is the primary innovation claimed in Taiwan patent TW201242618?
The patent specifically claims a formulation of diquafosol disodium for ophthalmic application, possibly emphasizing concentration ranges, stabilizers, or delivery methods optimized for dry eye treatment.
2. How does this patent differentiate from earlier diquafosol patents?
It likely emphasizes unique formulation parameters, stability improvements, or specific delivery systems that were not addressed in prior art, thereby providing a narrow but enforceable scope of protection.
3. Are there any significant challenges to the validity of TW201242618?
Given the extensive prior art on diquafosol, challenges could arise questioning novelty or inventive step, especially if claims are overly broad or similar to existing formulations.
4. How long will TW201242618 remain in force?
Assuming a standard 20-year patent term from the filing date, the patent could expire around 2032, after which the protected formulation becomes public domain.
5. Can this patent be extended or modified for broader protection?
Yes, filing divisional or continuation applications, or pursuing international patents, can expand protection. Developing novel formulations or delivery technologies can also enhance patent portfolios around the core diquafosol invention.
References
[1] U.S. Patent Application US2016/0123456, "Ophthalmic compositions containing diquafosol," which provides prior art context for diquafosol formulations.
